In the Headlines
July 12, 2017
F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment
The New York Times
If accepted by the Food and Drug Administration, the first gene-altering treatment for leukemia will be the first gene therapy ever on the market. Quality control and consistency with this treatment are among the main concerns regarding its manufacturing process.
“The fact that it can be done means more people will go into the field and more companies will start developing these products,” said Pharmaceutical, Biotechnology and Medical Device Industries Partner Michael Werner. “I think we’re in for really exciting times."
READ: F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment